Biotech Week articles from January 2001

Biotech Week archives from January 2001

Adenosine Kinase Inhibitors Can Provide New Mechanisms for Pain Relief.
January 17, 2001... 2001 JAN 17 - (NewsRx.com) --. - by Michael Greer, staff medical writer -- ABT-702, a highly selective inhibitor of the enzyme adenosine kinase, may be the basis for a novel mechanism for relieving pain, according to pharmaceutical researchers...

FDA Approval Granted for CFA Digital Imaging System.(Escalon Medical Corp.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Escalon Medical Corp. (ESMC), Wayne, Pennsylvania, announced that it was granted U.S. Food and Drug Administration (FDA) approval for its high-end digital camera system for ophthalmologists known as the CFA Digital...

U.S. Patent Office Invalidates Patent for 3TC/Epivir.(Emory Univeristy patent invalidated; BioChem Pharma Inc. patent upheld)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- BioChem Pharma Inc. (BCHE; TSE: BCH), Laval, Quebec, Canada, announced that the U.S. Board of Patent Appeals and Interferences has invalidated Emory University's (Atlanta, Georgia) patent for 3TC/Epivir...

European D-03 Clinical Study of VNS in Depression Announced.(vagus nerve stimulation for pharmacotherapy-resistant mental depression)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Cyberonics, Inc. (CYBX), Houston, Texas, announced the beginning of the European D-03 clinical study of Vagus Nerve Stimulation (VNS) for the treatment of depression at Beaumont Hospital in Dublin, Ireland. ...

Proprietary Substrates Licensed for Use in Drug Discovery and Gene Function Applications.(Odyssey Pharmaceuticals Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Odyssey Pharmaceuticals, Inc., San Ramon, California, announced that it has entered into a license agreement with BD (Becton, Dickinson and Company)(BDX) that grants Odyssey the sole right and license to certain...

Phase IIa Clinical Trial of Monoclonal Antibody Initiated.(Abgenix Inc. tests ABX-IL8)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Abgenix, Inc. (ABGX), Fremont, California, announced the start of a Phase IIa multi-center clinical trial of ABX-IL8 in patients with rheumatoid arthritis. The company is also conducting a Phase IIa clinical...

Phase II/III Trial Initiated for Treatment of Emotional Lability.(Avanir Pharmaceuticals starts trials of AVP-23)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Avanir Pharmaceuticals (AVN), San Diego, California, announced the initiation of a Phase II/III clinical trial of the AVP-23 drug candidate. This clinical trial is the first in a series of studies intended to...

FDA Reviews Application for Intranasal Vaccine.(Aviron application for FluMist intranasal influenza vaccine under review)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Aviron (AVIR) announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for FluMist, an investigational intranasal influenza vaccine. On October 31,...

Sirolimus-Coated Stent Still Effective at 12 Months' Follow-Up.(Cordis Corp.'s BX Velocity Coronary Stent)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Cordis Corp., Warren, New Jersey, reported pilot clinical results of its investigational Sirolimus pharmaceutical-coated Bx Velocity Coronary Stent revealed no evidence of restenosis at 12-month treatment follow-up...

Collaboration on Oral Antithrombotic Compound Announced.(between Sankyo Company Ltd. and Eli Lilly and Co.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Eli Lilly and Company (LLY), Indianapolis, Indiana, and Sankyo Company, Ltd., announced they have signed a letter of intent to collaborate on CS-747, a potentially potent antiplatelet agent that blocks ADP...

License Agreement Announced for Anti-Hepatitis B Compound.(between Mitsubishi-Tokyo Pharmaceuticals Inc. and Eli Lilly and Co.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Eli Lilly and Company (LLY and Tokyo: 4857), Indianapolis, Indiana, and Mitsubishi-Tokyo Pharmaceuticals, Inc., announced that they have signed a license agreement for MCC-478, for treatment of hepatitis B virus...

New Findings on Nicotine Cardiovascular Treatment to Be Highlighted.
January 17, 2001... 2001 JAN 17- (NewsRx.com) -- Endovasc Ltd. Inc. announced December 27, 2000, that investigators from the Stanford University School of Medicine will present new data during January 2001 on nicotine's role promoting the growth of new blood...

Company to Accelerate Development of Antibody-Based Therapeutics.(Immunomedics)
January 17, 2001... 2001 JAN 17- (NewsRx.com) -- Immunomedics (IMMU), Morris Plains, New Jersey, announced that the company is refocusing internal and certain external activities exclusively on its pipeline of cancer therapeutic antibodies. The company said...

Grant Awarded to Develop Therapy Techniques To Enhance Tumor Cells Sensitivity.(Introgen Therapeutics Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Introgen Therapeutics, Inc. (INGN), Austin, Texas, announced that it was awarded a Small Business Technology Transfer (STTR) grant from the U.S. National Cancer Institute (NCI). The grant will fund...

Exclusive License Announced for HPV Vaccines.(human papillomavirus vaccines)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- King Pharmaceuticals, Inc. (KG), Bristol, Tennessee, announced that it has obtained an exclusive license from Novavax, Inc. (NOX) to use its proprietary cell line to develop and potentially commercialize...

Three Regulatory Approvals Announced for Implantable Systems.(Medtronic Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Medtronic, Inc., Minneapolis, Minnesota, announced three milestones in the therapeutic delivery of electrical stimulation to treat diseases in which the heart beats too fast. The regulatory approval milestones...

U.S. Patent Awarded on Method for Detecting Nucleic Acid Hybridization.(Nanogen Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Nanogen, Inc. (NGEN), San Diego, California, announced that on December 19, 2000, it was awarded an additional U.S. patent relating to its electronic microarray technology. U.S. Patent No. 6,162,603, entitled...

FDA Approval for Starlix Received.(Novartis Pharmaceuticals Corp.)
January 17, 2001... 2001 JAN 17- (NewsRx.com) -- Novartis Pharmaceuticals Corp., East Hanover, New Jersey, received marketing approval from the U.S. Food and Drug Administration (FDA) for Starlix (nateglinide) for the treatment of type 2 diabetes. Starlix, a...

New Treatment for Type 2 Diabetes Gains FDA Approval.(Novartis Pharmaceuticals' Starlix)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Novartis Pharmaceuticals Corporation received marketing approval December 22, 2000, from the U.S. Food and Drug Administration (FDA) for Starlix (nateglinide) for the treatment of type 2 diabetes, a disease with...

Phase I Clinical Trial Initiated.(by Pfizer Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- OSI Pharmaceuticals, Inc. (OSIP), Uniondale, New York, announced that Pfizer Inc. (PFE) has opened an IND for Phase I clinical trials in the United States to evaluate a small molecule anticancer drug designed to...

Composite Cultured Skin Seeks FDA Marketing Approval.(Ortec International Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Ortec International, Inc., announced December 28, 2000, that the clinical data from its recently concluded pivotal (final stage) clinical trial evaluating the use of its Composite Cultured Skin (CCS) for...

Investigational New Drug Application Submission Announced.(Praecis Pharmaceuticals Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Praecis Pharmaceuticals Inc. (PRCS), Cambridge, Massachusetts, announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug application (IND) to initiate Phase I clinical...

Study Demonstrates Effectiveness on High-Grade Lesions.(Spectranetics Corp. catheters tested in coronary artery blockage removal study)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- The Spectranetics Corp. (SPNC), Colorado Springs, Colorado, announced that Luc Bilodeau, MD, Montreal Heart Institute, Montreal, Quebec, and David Hilton, MD, Royal Jubilee Hospital in Victoria, British Columbia,...

Collaboration Established on High Throughput Discovery of Genes Associated with Disease.(Third Wave Technologies Inc. in collaboration with Catalyst BioMedica Ltd. and Cambridge University)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Third Wave Technologies, Inc., Madison, Wisconsin, announced that it has entered into a research collaboration agreement with the Wellcome Trust's business subsidiary Catalyst BioMedica Ltd. and Cambridge...

Clinical Data Submitted Seeking Expanded Claims for Diagnostic Systems.(TriPath Imaging Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- TriPath Imaging, Inc. (TPTH) (TriPath), Burlington, North Carolina, announced that the company has submitted new clinical data to the U.S. Food and Drug Administration (FDA) to support applications to expand the...

Company Reports on Cytokine Combination Gene Medicine.(Valentis Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Valentis, Inc. (VLTS), Burlingame, California, presented results from preclinical studies demonstrating a synergistic increase in anti-tumor response by a gene medicine that combines the interleukin-12 (IL-12) and...

Approval Granted in France for Trugene HIV-1 Kit.(Visible Genetics Inc.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- Visible Genetics Inc. (VGI) (VGIN), Toronto, Ontario, Canada, reported that it has been granted French regulatory approval for its Trugene HIV-1 Genotyping Kit by the Agence Francaise De Securite Sanitaire Des...

Company Provides Update on Development of Monoclonal Antibody Therapy.(XTL Biopharmaceuticals Ltd.)
January 17, 2001... 2001 JAN 17 - (NewsRx.com) -- XTL Biopharmaceuticals Ltd. (XTL) (XTL) presented preclinical data on the company's human monoclonal antibody products (including XTL-002) being developed to treat the hepatitis C virus (HCV). The information...

Pharmaceuticals from Microalgae Pursued.(Aquasearch Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Aquasearch, Inc. (AQSE) executed an agreement to develop pharmaceuticals from a collection of more than 2,000 strains of microalgae held by University of Hawaii (UH), Kailua-Kona. The collection has already...

Gene Therapy Program Data Published.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Avax Technologies, Inc. (AVXT), Kansas City, Missouri, announced that data relating to its thymidine kinase (TK) suicide gene program for organ transplantation were published in the December 2000 issue of Molecular...

Technology Could Help Produce New Antibiotics.("gene chip" technology)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Under the looming threat of antibiotic resistance, scientists are working to develop the next generation of bacteria-destroying drugs. In the January 2001 issue of Genome Research, researchers from Hoffman-La...

Therapeutic Target Discovered for Breast and Ovarian Cancer.(Immusol Inc.'s Inverse Genomics technology)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Immusol, Inc, San Diego, California, announced that the company's proprietary Inverse Genomics technology led to the discovery of a potential drug target gene for breast and ovarian cancer. Immusol's work is...

Positive Results Announced in Patients Treated with INS-1.(new type 2 diabetes therapy consisting of INS-1 and sulfonylureas)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Insmed Incorporated announced January 4, 2001, positive results following a full analysis of its recently completed clinical trial of type 2 diabetes patients treated with INS-1 in combination with sulfonylureas....

ALT-711 Demonstrates Potential as Treatment for ISH.(Alteon Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Alteon Inc. (ALT), Ramsey, New Jersey, announced positive results from a Phase IIa clinical trial evaluating the safety, efficacy and pharmacology of ALT-711. ALT-711 is an Advanced Glycosylation End-product...

Alliance Formed to Develop Diagnostic Products.(between Millennium Pharmaceuticals Inc. and Roche Diagnostics)
January 24, 2001... 2001 JAN 24- (NewsRx.com) -- Millennium Pharmaceuticals, Inc. (MLNM), Cambridge, Massachusetts, together with its wholly-owned subsidiary Millennium Predictive Medicine, Inc., and Roche Diagnostics, a division of the Roche Group (ROCZ.S),...

Phase II Trial to Begin Shortly in United Kingdom.(NeoTherapeutics Inc. and NeoOncoRX Inc. to test anti-cancer compound E09 and 79 analogs)
January 24, 2001... 2001 JAN 24- (NewsRx.com) -- NeoTherapeutics, Inc. (NEOT, NEOTW), Irvine, California, announced that its newly formed anti-cancer subsidiary, NeoOncoRx, Inc., has signed a letter of intent to acquire anti-cancer compound E09 and 79 analogs from...

License Issued for AquaFlow Medical Device.(STAAR Sugical Co. receives license from Health Canada Agency)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- STAAR Surgical Co. (STAA), Monrovia, California, announced that it has received a Medical Device License from the Canadian government (Health Canada Agency) that allows the company to market and distribute the...

Collaboration Provides Automated Cell-Based Transcription Assay.(Zymark and Bayer Corp. Diagnostics Div.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Zymark and Bayer Corporation's Diagnostics Business Group are pleased to announce a collaborative effort providing an automated platform for cell-based compound screening. The assay solutions package,...

Phase IIb ABX-IL8 Study to Proceed.(Abgenix Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Abgenix, Inc. (ABGX), Fremont, California, announced the decision to proceed with a Phase IIb clinical trial of ABX-IL8 in patients with moderate-to-severe psoriasis. The decision to move forward is based on...

Cancer Screening System Clinical Trial in China Commenced.(by Ampersand Medical Corp.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Ampersand Medical Corp. (AMPM), Chicago, Illinois, announced the commencement of a clinical trial in China using the InPath System, a screening system for cervical cancer. The trial is the first step in a...

Investment Received to Pursue Non-Invasive Therapeutic Ultrasound.(Angiosonics Inc. receives investment from Tyco Ventures for lipolysis treatment)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Angiosonics, Inc., Morrisville, North Carolina, announced that Tyco Ventures is the lead investor in the first round of financing for Lipolysis, Inc. This round of financing will allow Angiosonics to pursue...

Cell-Elimination Technology Has Therapy and Vaccine Potential.(Ariad Pharmaceuticals Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Ariad Pharmaceuticals, Inc., reported January 8, 2001, the results of in viva studies demonstrating promising new applications of its Argent [TM] regulated cellelimination technology for both the treatment and...

Zestril Studied in for Prevention.(of migraine)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- AstraZeneca's angiotensin converting enzyme (ACE) inhibitor, Zestril (lisinopril) 20 mg once daily demonstrated a 21% reduction in the number of days with migraine attack and lowered the headache severity index by...

Phase IIb TP10 Study Begins in Infants Undergoing High Risk Cardiac Surgery.(Avant Immunotherapeutics Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Avant Immunotherapeutics, Inc. (AVAN) announced the start of a placebo-controlled, Phase IIb trial of its lead complement inhibitor, TP10, in approximately 30 infants undergoing high risk cardiac surgery involving...

Pivotal Studies Evaluate Envision TD Technology.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Bausch & Lomb and Control Delivery Systems, Inc. have begun enrolling patients in Phase IIB/III clinical studies to evaluate the effectiveness of Envision TD[TM] intravitreal implants with fluocinolone acetonide in...

Bayer Develops Experimental Cancer Treatment by Targeting Genetic Code.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- German drug maker Bayer AG will begin human testing of a new cancer treatment that taps revolutionary research targeting genes linked to the illness, the company said. The method has successfully halted tumor...

European Orphan Drug Designation Received for rhASB for MPS-VI.(BioMarin Pharmaceutical Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- BioMarin Pharmaceutical Inc. (BMRN), Novato, California, announced that the Committee for Orphan Medical Products of the European Agency for the Evaluation of Medicinal Products (COMP/EMEA) has rendered a positive...

Tumor-Specific Vaccines Under Development.(BioPulse International Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- BioPulse International, Inc., (BIOP), San Ysidro, California, announced the development of multiple Tumor-Specific Cancer Vaccines (TSV). The vaccines are based on the company's dendritic cell cancer vaccine...

Hemopure Phase III Clinical Trial Update Presented.(Biopure Corp.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Biopure Corp. (BPUR), Cambridge, Massachusetts, has held an "end of Phase III" meeting with the U.S. Food and Drug Administration (FDA) and is proceeding with preparations to file a Biologic License Application...

Production Method Conserves Biological Activity of Native Protein.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Dr. Irene Gonzalez, Boston Life Sciences, Inc. (BLSI), has developed a proprietary method for the purification of complex bacterial-produced recombinant proteins that conserves the biological activity of the native...

CARISA Trial Enrollment Updated.(Combination Assessment of Ranolzaine In Stable Angina)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- CV Therapeutics, Inc. (CVTX), Palo Alto, California, announced that it has completed enrollment of the originally planned 462 patients in the Phase Ill CARISA (Combination Assessment of Ranolazine In Stable Angina)...

Grant Awarded for Drug Discovery to Treat Peripheral Nerve Dysfunction.(Cambridge NeuroScience Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Cambridge NeuroScience, Inc., Norwood, Massachusetts, announced that it has been awarded a two-year Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Neurological Diseases...

3D Surgical Visualization and Navigation Technology Patent Received.(by Cbyon Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Cbyon, Inc., Palo Alto, California, announced that the U.S. Patent and Trademark Office issued a broad, enabling patent related to the company's surgical navigation technology. The technology is marketed as...

Patent Issued for Measuring Quantity and Quality of DNA in Samples.(Exact Sciences Corp.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Exact Sciences Corporation, an applied genomics company developing screening technologies for the early detection of cancer, announced January 3, 2001, the issuance of its tenth U.S. Patent, No. 6,143,529, titled...

Fecal Blood Screens Reduce Incidence.(of colorectal cancer)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Regular screening of blood hidden in fecal matter for signs of colorectal cancer significantly reduces not only the chance of fatality from the disease, but the chance of malignancy arising in the first place,...

Hepatitis-C-Related Notice of Invention Filed with Patent Office.(by the California Institute of Molecular Medicine)
January 24, 2001... 2001 JAN 24- (NewsRx.com) -- Hemispherx Biopharma, Inc., announced that the California Institute of Molecular Medicine (CIMM) has filed a Notice of Invention with the U.S. Patent Office titled "Replication of human Kupffer's cells obtained from...

Immunotherapy Added to First Cycle of Antiviral Cocktails.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Hemispherx Biopharma, Inc., announced January 3, 2001, a newly reviewed U.S. Food and Drug Administration (FDA) clinical protocol designed to test the blunting of the emergence of drug-resistant HIV strains. ...

Ibritumomab Tiuxetan Under Evaluation for Lymphatic Cancers.(IDEC Pharmaceuticals Corp.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- IDEC Pharmaceuticals Corporation announced January 2, 2001, that the Biologics License Application (BLA) for Zevalin [TM] (ibritumomab tiuxetan) has been accepted for filing by the U.S. Food and Drug Administration...

Phase II Study of Humanized Antibody Initiated.(IDEC Pharmaceuticals)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- IDEC Pharmaceuticals announced January 4, 2001, that it has initiated a Phase II clinical trial with its investigational agent, IDEC-131, a humanized anti-CD154 (anti-CD40L) monoclonal antibody. The...

Patent Claims Allowance Received for Technology.(Lynx Therapeutics Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Lynx Therapeutics, Inc. (LYNX), Hayward, California, announced the U.S. Patent Office granted an allowance of important system and method claims in Lynx's patent filings covering its proteomics technology. The...

Collaboration Initiated to Develop New Drugs.(Maxia Pharmaceuticals Inc. has collaboration with R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Maxia Pharmaceuticals, Inc., San Diego, California, announced that it has initiated a multi-year collaboration with The R.W. Johnson Pharmaceutical Research Institute (PRI) and Ortho-McNeil Pharmaceutical, Inc....

Collaboration Established to Accelerate Antibody Research.(Medarex Inc., Biosite Diagnostics Inc., and Eli Lilly and Co.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Medarex, Inc. (MEDX), Princeton, New Jersey, Eli Lilly and Company (LLY), Indianapolis, Indiana, and Biosite Diagnostics Inc. (BSTE), San Diego, California, announced a collaborative agreement under which Biosite...

Phase III Trial Begins for PolyphenonE to Treat Genital Warts.(MediGene AG)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- MediGene AG, Munich, Germany, announced that a Phase III trial for PolyphenonE to treat genital warts caused by Human Papillomaviruses was initiated in December 2000. The multi-center clinical trial will...

Technology Underlies Generation of Antibiotics Against Hospital Infections.(NewBiotics Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- NewBiotics Inc., San Diego, California, announced the issuance of U.S. Patent 6,159,706, broadly covering its "Trojan Horse" technology for killing antibiotic-resistant bacteria using the pathogen's own resistance...

Study Results Show Topical Photodynamic Therapy Effective Against Superficial Basal Cell Carcinoma.(PhotoCure ASA)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- PhotoCure ASA, London, United Kingdom, announced positive results from its first Phase III study on primary superficial basal cell carcinoma (BCC). In this study, more than 90% of the skin cancer lesions were...

Collaboration Will Analyze Population Genetic Profiles for Poor Drug Metabolism.(QIAGEN Genomics Inc. has collaboration with Genomics Collaborative Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- QIAGEN Genomics, Inc., and Genomics Collaborative, Inc., (GCI) announced January 8, 2001, that they have entered into a collaboration to analyze genetic profiles of geographically distinct patient populations with...

Patients Enrolled in Phase I Paclitaxel Formulation Study.(SONUS Pharmaceuticals Inc.)
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- Sonus Pharmaceuticals, Inc. (SNUS) announced that patients are being enrolled in a Phase I clinical study with the company's first drug delivery product, S-8184, an injectable paclitaxel emulsion formulation. ...

Supreme Spiral SC Catheters Release Announced.
January 24, 2001... 2001 JAN 24 - (NewsRx.com) -- St. Jude Medical Inc. (STJ), St. Paul, Minnesota, announced the global market release of electrophysiology catheters to assist clinicians in the diagnosis of paroxysmal atrial fibrillation (PAF). The Supreme...

Bicyclic Lactam-Based Thrombin Inhibitors Show Promise for Treatment.(of venous and arterial thrombosis)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- - by Michael Greer, staff medical writer -- A new class of thrombin inhibitors based on bicyclic lactams has great potential for the treatment of both venous and arterial thrombosis, researchers reported in the...

Data from Largest SNP Validation Study Published.(single nucleotide polymorphism)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- Sequenom [TM], Inc. (SQNM), announced on January 16, 2001, the publication of the results from its large-scale single nucleotide polymorphism (SNP) assay development and validation study undertaken in collaboration...

Progress Reported in Vascular Targeting Program.(OXiGENE Inc.'s Combretastin A4 Prodrug trials)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- OXiGENE, Inc. (OXGN), Watertown, Massachusetts, provided an update from its clinical trials of Combretastatin A4 Prodrug (CA4P). David Sherris, PhD, OXiGENE, presented data supporting CA4P's vascular targeting...

Researchers Study Treatment Options for "Eye Attacks".(ischematic optic neuopathy)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- The terms "heart attack" and "brain attack" have become commonplace, but now neuro-ophthalmologists are waging war on the all too common, underreported, and untreated condition referred to as "eye attacks." ...

Campylobacter Vaccine Exhibits Significant Immune Responses in Phase II Clinical Trial.
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- Antex Biologics Inc. (ANX), Gaithersburg, Maryland, announced that a recently completed Phase II clinical trial of Camnpyvax, the company's vaccine to prevent Campylobacter infections, showed significant immune...

Results of Phase I Study of CETP Vaccine for Low HDL Announced.
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- Avant Immunotherapeutics (AVAN), Needham, Massachusetts, announced the results of a double-blind placebo controlled, Phase I trial of its CETP vaccine (CETi-1) in 48 healthy adult volunteers. The objective of...

"Smart Probe" Detects Malignant Tumors Instantly.(breast cancer diagnosis)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- The pain and anxiety women experience undergoing breast cancer tests and awaiting the results might soon be lessened due to the "Smart Probe," which can instantly detect cancerous tissue. Lawrence Livermore...

HIV Combination Therapy Caution Issued for Pregnant Women.(possible risk of fatal lactic acidosis with use of stavudine and didanosine with other antiretroviral agents)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- The U.S. Food and Drug Administration (FDA) and Bristol Myers Squibb are warning health care professionals that pregnant women may be at increased risk of fatal lactic acidosis when prescribed the combination of...

Investigational New Drug Application for NM-3 Filed.(angiogenesis inhibitor)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) --Ilex Products Inc., a wholly owned subsidiary of flex Oncology Inc. (ILXO), announced that an Investigational New Drug (INI)) application has been submitted to the U.S. Food and Drug Administration for the product...

Monoclonal Antibody Inhibits HIV Entry into Cells.(PRO 140)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- Progenics Pharmaceuticals, Inc. (PGNX), Tarrytown, New York, announced the publication of a scientific article describing PRO 140, an inhibitor of HIV entry, which demonstrates broad and potent antiviral activity...

Ribozyme Targets Hepatitis B RNA Transcripts.(HepBzyme)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- Ribozyme Pharmaceuticals, Inc. (RPI) (RZYM), Boulder, Colorado, announced the selection of its product candidate, HepBzyme, targeting the hepatitis B virus (HBV). This ribozyme targets several HBV RNA...

Pegylated Interferon-alpha Therapy Profiled for Chronic Hepatitis C Patients.
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- by Sonia Bell-Nichols, staff medical writer -- Pegylated interferon-alpha 2b, when taken once a week, demonstrates the same efficacy as thrice-weekly doses of non-pegylated interferon-alpha 2b, a common treatment...

Pivotal U.S. Phase III Program Begins with Zadaxin Plus Pegylated Alfa Interferon.(for treatment of Hepatitis C)
January 31, 2001... 2001 JAN 31 - (NewsRx.com) -- SciClone Pharmaceuticals (SCLN), San Mateo, California, announced that it has initiated its pivotal U.S. Phase III hepatitis C clinical program for Zadaxin in combination with Pegasys, pegylated interferon alfa-2a....